{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:54:39Z","timestamp":1792173279758,"version":"4.4.0"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1998,9,16]]},"DOI":"10.1093\/jnci\/90.18.1371","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T18:24:57Z","timestamp":1027707897000},"page":"1371-1388","source":"Crossref","is-referenced-by-count":4373,"title":["Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study"],"prefix":"10.1093","volume":"90","author":[{"given":"Bernard","family":"Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Lawrence","family":"Wickerham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol K.","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Kavanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter M.","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Robidoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay","family":"Dimitrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Wieand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Tan-Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Wolmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"other National Surgical Adjuvant Breast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Bowel Project Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[1998,9,16]]},"reference":[{"key":"key\n\t\t\t\t20180328133546_R1","first-page":"1463","article-title":"Current overview of EORTC clinical trials with tamoxifen","volume":"60","author":"Heuson","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"key\n\t\t\t\t20180328133546_R2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0305-7372(78)80017-6","article-title":"Tamoxifen in advanced breast cancer","volume":"5","author":"Mouridsen","year":"1978","journal-title":"Cancer Treat Rev"},{"key":"key\n\t\t\t\t20180328133546_R3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.1979.03300010033023","article-title":"Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy","volume":"242","author":"Legha","year":"1979","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328133546_R4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF01806987","article-title":"Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer","volume":"4","author":"Margreiter","year":"1984","journal-title":"Breast Cancer Res Treat"},{"key":"key\n\t\t\t\t20180328133546_R5","first-page":"51","article-title":"Tamoxifen and other antiestrogens","volume-title":"In: Powles TJ, Smith IE, editors. Medical management of breast cancer","author":"Jackson","year":"1991"},{"key":"key\n\t\t\t\t20180328133546_R6","first-page":"257","article-title":"Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation","volume":"1","year":"1983","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133546_R7","first-page":"836","article-title":"Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation","volume":"1","year":"1985","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133546_R8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1200\/JCO.1986.4.4.459","article-title":"Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial","volume":"4","author":"Fisher","year":"1986","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180328133546_R9","first-page":"171","article-title":"Edinburgh","volume":"2","author":"Adjuvant","year":"1987","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133546_R10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJM198902233200802","article-title":"A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptorpositive tumors","volume":"320","author":"Fisher","year":"1989","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133546_R11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/bjc.1988.137","article-title":"CRC Adjuvant Breast Trial Working Party. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer","volume":"57","year":"1988","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20180328133546_R12","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/83.18.1299","article-title":"Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy","volume":"83","author":"Rutqvist","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20180328133546_R13","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/jnci\/83.18.1278","article-title":"New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent [editorial]","volume":"83","author":"Fisher","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20180328133546_R14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/bjc.1989.235","article-title":"A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer","volume":"60","author":"Powles","year":"1989","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20180328133546_R15","first-page":"355","article-title":"Tamoxifen (review)","volume-title":"In: Goldberg ME, editor. Pharmacological and biochemical properties of drug substances. Vol 2.","author":"Furr","year":"1979"},{"key":"key\n\t\t\t\t20180328133546_R16","first-page":"131","article-title":"Pharmacokinetic studies with Nolvadex","volume":"(9 Suppl)","author":"Adam","year":"1981","journal-title":"Reviews on Endocrine- Related Cancer"},{"key":"key\n\t\t\t\t20180328133546_R17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0022-4731(84)90197-3","article-title":"Non-steroidal antioestrogens\u2014 receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells","volume":"20","author":"Wakeling","year":"1984","journal-title":"J Steroid Biochem"},{"key":"key\n\t\t\t\t20180328133546_R18","first-page":"4517","article-title":"Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III","volume":"47","author":"Jordan","year":"1987","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t20180328133546_R19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0014-2964(71)90096-X","article-title":"Effect of anti-oestrogens on initiation of mammary cancer in the female rat","volume":"7","author":"Terenius","year":"1971","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20180328133546_R20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0014-2964(76)90030-X","article-title":"(ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata","volume":"12","author":"Jordan","year":"1976","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20180328133546_R21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0014-2964(80)90156-5","article-title":"Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model","volume":"16","author":"Jordan","year":"1980","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20180328133546_R22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0021-9150(84)90064-9","article-title":"Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen","volume":"52","author":"Rossner","year":"1984","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180328133546_R23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF01811244","article-title":"Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels","volume":"12","author":"Bertelli","year":"1988","journal-title":"Breast Cancer Res Treat"},{"key":"key\n\t\t\t\t20180328133546_R24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/bjc.1988.248","article-title":"Tamoxifen, serum lipoproteins and cardiovascular risk","volume":"58","author":"Bruning","year":"1988","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20180328133546_R25","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/jnci\/82.16.1327","article-title":"Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer","volume":"82","author":"Love","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20180328133546_R26","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1210\/jcem-70-4-1132","article-title":"Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition","volume":"70","author":"Bagdade","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t20180328133546_R27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0163-7258(84)90043-3","article-title":"The pharmacology and clinical uses of tamoxifen","volume":"25","author":"Furr","year":"1984","journal-title":"Pharmacol Ther"},{"key":"key\n\t\t\t\t20180328133546_R28","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effect of tamoxifen on bone mineral density in postmenopausal women with breast cancer","volume":"326","author":"Love","year":"1992","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328133546_R29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/107327489700400111","article-title":"Highlights of the NSABP breast cancer prevention trial","volume":"4","author":"Fisher","year":"1997","journal-title":"Cancer Control"},{"key":"key\n\t\t\t\t20180328133546_R30","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","article-title":"Projecting individualized probabilities of developing breast cancer for white females who are being examined annually","volume":"81","author":"Gail","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20180328133546_R31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/biomet\/58.3.403","article-title":"Forcing a sequential experiment to be balanced","volume":"58","author":"Efron","year":"1971","journal-title":"Biometrika"},{"key":"key\n\t\t\t\t20180328133546_R32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0197-2456(84)80014-8","article-title":"Designs for group sequential tests","volume":"5","author":"Fleming","year":"1984","journal-title":"Controlled Clin Trials"},{"key":"key\n\t\t\t\t20180328133546_R33","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0197-2456(96)00016-5","article-title":"Approaches to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative","volume":"17","author":"Freedman","year":"1996","journal-title":"Controlled Clin Trials"},{"key":"key\n\t\t\t\t20180328133546_R34","first-page":"590","volume-title":"Fundamentals of biostatistics. 4th ed.","author":"Rosner","year":"1995"},{"key":"key\n\t\t\t\t20180328133546_R35","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/sim.4780110611","article-title":"Applications of crude incidence curves","volume":"11","author":"Korn","year":"1992","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20180328133546_R36","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/014662167700100306","article-title":"The CES-D scale: a self-report depression scale for research in the general public","volume":"1","author":"Radloff","year":"1977","journal-title":"Appl Psychol Meas"},{"key":"key\n\t\t\t\t20180328133546_R37","doi-asserted-by":"crossref","DOI":"10.7249\/CB361","article-title":"Measuring functioning and well-being: the Medical Outcomes Study approach","author":"Stewart","year":"1992"},{"key":"key\n\t\t\t\t20180328133546_R38","first-page":"1381","article-title":"Role of retinoids in differentiation and carcinogenesis","volume":"73","author":"Sporn","year":"1984","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20180328133546_R39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/0147-0272(94)90003-5","article-title":"Chemoprevention of cancer","volume":"18","author":"Szarka","year":"1994","journal-title":"Curr Probl Cancer"},{"key":"key\n\t\t\t\t20180328133546_R40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/oxfordjournals.aje.a116267","article-title":"Prospects for the primary prevention of breast cancer","volume":"135","author":"Bernstein","year":"1992","journal-title":"Am J Epidemiology"},{"key":"key\n\t\t\t\t20180328133546_R41","first-page":"984","article-title":"Chemoprevention","volume":"72(3 Suppl)","author":"Lippman","year":"1993","journal-title":"Strategies for the control of cancer. Cancer"},{"key":"key\n\t\t\t\t20180328133546_R42","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jnci\/80.11.802","article-title":"Aspects of the rationale for the Women's Health Trial","volume":"80","author":"Prentice","year":"1988","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20180328133546_R43","first-page":"93","article-title":"Chemoprevention of breast cancer with retinoids","volume":"12","author":"Veronesi","year":"1992","journal-title":"J Natl Cancer Inst Monogr"},{"key":"key\n\t\t\t\t20180328133546_R44","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.2820690518","article-title":"Estrogen receptor immunohistochemistry in carcinoma in situ of the breast","volume":"69","author":"Bur","year":"1992","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20180328133546_R45","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/bjc.1993.305","article-title":"Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein","volume":"68","author":"Poller","year":"1993","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20180328133546_R46","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2559.1989.tb01623.x","article-title":"Oestrogen receptors in benign epithelial lesions and intraductal carcinomas of the breast: an immunohistological study","volume":"15","author":"Giri","year":"1989","journal-title":"Histopathology"},{"key":"key\n\t\t\t\t20180328133546_R47","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/ajcp\/94.5.533","article-title":"Potential value of hormone receptor assay in carcinoma in situ of breast","volume":"94","author":"Barnes","year":"1990","journal-title":"Am J Clin Pathol"},{"key":"key\n\t\t\t\t20180328133546_R48","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/jnci\/85.17.1398","article-title":"Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen","volume":"85","author":"Rutqvist","year":"1993","journal-title":"The Stockholm Breast Cancer Study Group. J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20180328133546_R49","first-page":"977","article-title":"Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial","volume":"311","author":"McDonald","year":"1995","journal-title":"The Scottish Cancer Trials Breast Group. BMJ"},{"key":"key\n\t\t\t\t20180328133546_R50","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/jnci\/89.11.776","article-title":"Coronary heart disease mortality and adjuvant tamoxifen therapy","volume":"89","author":"Costantino","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20180328133546_R51","doi-asserted-by":"crossref","first-page":"516","DOI":"10.7326\/0003-4819-112-7-516","article-title":"Screening for osteoporosis","volume":"112","author":"Melton","year":"1990","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180328133546_R52","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","article-title":"Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors","volume":"88","author":"Fisher","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20180328133546_R53","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1200\/JCO.1998.16.2.779","article-title":"Does tamoxifen cause cancer in humans?","volume":"16","author":"Stearns","year":"1998","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180328133546_R54","first-page":"1","volume-title":"ACOG committee on Gynecologic Practice. Committee opinion","year":"1996"},{"key":"key\n\t\t\t\t20180328133546_R55","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/0959-8049(96)00184-0","article-title":"A realistic clinical perspective of tamoxifen and endometrial carcinogenesis","volume":"32A","author":"Assikis","year":"1996","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20180328133546_R56","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1698::AID-CNCR16>3.0.CO;2-#","article-title":"The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma","volume":"82","author":"Katase","year":"1998","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20180328133546_R57","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1200\/JCO.1998.16.6.2018","article-title":"Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes","volume":"16","author":"Ragaz","year":"1898","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180328133546_R58","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1993.11.3.485","article-title":"High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients","volume":"11","author":"Magriples","year":"1993","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180328133546_R59","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.1996.14.3.1027","article-title":"A commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients","volume":"14","author":"Fisher","year":"1996","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180328133546_R60","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","article-title":"Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14","volume":"86","author":"Fisher","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20180328133546_R61","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0002-9394(99)80190-1","article-title":"Long-term tamoxifen citrate use and potential ocular toxicity","volume":"125","author":"Gorin","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"key\n\t\t\t\t20180328133546_R62","first-page":"105","article-title":"Systemic therapy in node-negative patients: updated findings from NSABP clinical trials","volume":"11","author":"Fisher","year":"1992","journal-title":"National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst Monogr"},{"key":"key\n\t\t\t\t20180328133546_R63","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.1991.9.2.286","article-title":"Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer","volume":"9","author":"Saphner","year":"1991","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180328133546_R64","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/bjc.1988.138","article-title":"Nolvadex' Adjuvant Trial Organisation. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer","volume":"57","year":"1988","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20180328133546_R65","first-page":"2a","article-title":"Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial [abstract]","volume":"17","author":"Cummings","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"key\n\t\t\t\t20180328133546_R66","first-page":"93","article-title":"Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women","volume":"352","author":"Veronesi","year":"1998","journal-title":"Italian Tamoxifen Prevention Study. Lancet"},{"key":"key\n\t\t\t\t20180328133546_R67","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(98)85012-5","article-title":"Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial","volume":"352","author":"Powles","year":"1998","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180328133546_R68","first-page":"115","article-title":"International classification of diseases. 9th rev","volume-title":"Clinical modification. 5th ed.","year":"1997"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/90\/18\/1371\/18048254\/90-18-1371.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T03:25:02Z","timestamp":1583292302000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/90\/18\/1371\/897928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,9,16]]},"references-count":68,"journal-issue":{"issue":"18","published-online":{"date-parts":[[1998,9,16]]},"published-print":{"date-parts":[[1998,9,16]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/90.18.1371","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1998,9,16]]},"published":{"date-parts":[[1998,9,16]]}}}